TVA Medical (Austin, TX) a development-stage medical device company focused on a minimally invasive approach for the treatment of end-stage renal disease, closed a $2.6M Series A financing. Participants include Santé Ventures.

Savara Pharmaceuticals (Austin, TX) a development-stage Dry powder and nebulizer-based drug delivery solution, closed a $1.4M Series A financing. Participants were not identified.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Ortho Kinematics (Austin, TX) a development-stage spine diagnostics company focused on inter-vertebral motion analysis, closed a $2M Series A financing. Participants include PTV Sciences, Texas Emerging Technology Fund and Gatebridge Investments.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Terapio (Austin, TX) a preclinical-stage biopharmaceutical company focused on radiodermatitis, closed a $5M Series A financing. Participants have included Santé Ventures and Texas Emerging Technology Fund.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Bellicum Pharmaceuticals (Houston, TX) a clinical-stage biopharmaceutical company focused on immune-modulating therapeutic vaccines for prostate cancer, closed a $4.5M Series A financing. Particiapnts include the Texas Emerging Technology Fund.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Vidacare (San Antonio, TX) a commercial-stage medical device company focused on enabling intraosseous access technologies, closed a $7.6M Series D financing. Participants include Piper Jaffray, Telegraph Hill Partners, Tullis Health Investors and Incyte Venture.

eCardio Diagnostics (The Woodlands, TX) a X-stage company focused on the diagnosis, monitoring and clinical management of cardiac arrhythmias, closed a $10M Series B financing.* Participants include Sequoia Capital.
*This statement estimates undisclosed financial information

SynCardia Systems (Tuscan, AZ) commercial-stage manufacturer of the temporary cardiowest total artificial heart, closed a $10.3M Series D financing. Participants include Highway 12 Ventures.

Savara Pharmaceuticals (Austin, TX) a preclinical-stage developer of dry powder and nebulized-based therapeutic inhalation drug delivery platform, closed a $1.0M Series A financing. Participants were not identified.

Glycos Biotechnologies (Houston, TX) a development-stage biofuels company focused on production of intermediate chemicals for biodegradable, non-degradable plastics, surfactants and fuels, closed a $5M Series A financing. Participants include Draper Fisher Jurvetson and DFJ Mercury.